Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197910 | 0.86 | NPC1 (0.67) | NPC1ALDH1A1MEN1POLBMAPT | |
| SCHEMBL3315105 | 0.85 | NPC1 (0.43) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL12536206 | 0.82 | ALDH1A1 (0.43) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL12876362 | 0.82 | EPHX2 (0.46) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL12015005 | 0.82 | NPC1 (0.47) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL18232473 | 0.81 | CPN1 (0.47) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL22874723 | 0.81 | NPC1 (0.46) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL4150889 | 0.81 | GNAI3 (0.57) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL20233003 | 0.80 | NPC1 (0.42) | NPC1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL13747823 | 0.80 | IRAK4 (0.42) | NPC1ALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | NPC1 19/4885ALDH1A1 2378/4885GNAI3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.